Theta Burst Stimulation as a Tool to Decrease Drinking in Treatment-seeking Alcohol Users

  • STATUS
    Recruiting
  • End date
    Aug 12, 2024
  • participants needed
    180
  • sponsor
    Wake Forest University Health Sciences
Updated on 12 June 2021
anxiety
heavy drinking
alcohol use disorder

Summary

There is growing interest in the utilization of transcranial magnetic stimulation (TMS) as a novel, non-pharmacologic approach to decreasing alcohol use among treatment-seeking individuals with Alcohol Use Disorder (AUD). The results of this study will be used to determine which of the 2 proposed TMS strategies has a larger effect on drinking behavior (% days abstinent, % heavy drinking days) as well as alcohol cue-reactivity in a 4 month period. These data will pave the way for TMS to be used as an innovative, new treatment option for individuals with AUD.

Description

Alcohol Use Disorder (AUD) is prevalent, devastating, and difficult to treat. The majority of therapeutic approaches to date have relied on pharmaceutical modulation or and/or psychotherapy. With a growing knowledge of the neural circuits that contribute to relapse in AUD, there is an emerging interest in developing a novel, neural-circuit specific therapeutic tool to enhance AUD treatment outcomes. The long term goal of this multidisciplinary research team is to develop an evidence-based brain stimulation treatment protocol which will improve AUD treatment outcomes. The competing neurobehavioral decision systems (CNDS) theory posits that in addiction, choice results from a regulatory imbalance between two decision-making systems (impulsive and executive). These behavioral systems are functionally linked to two discrete frontal-striatal circuits which regulate limbic and executive control. Modulating these competing neural circuits (e.g. either dampening the limbic/impulsive system or amplifying the executive control system) may render alcohol users less vulnerable to relapse. These two frontal-striatal neural circuits - the limbic loop (ventromedial prefrontal cortex (VMPFC)-ventral striatum), and executive control loop (dorsolateral PFC (DLPFC)-dorsal striatum) can be differentially stimulated by theta burst stimulation (TBS), a patterned form of transcranial magnetic stimulation. Continuous TBS (cTBS) results in long term depression (LTD) of cortical excitability and intermittent TBS (iTBS) results in long term potentiation (LTP).

Over the past 7 years, through the scaffolding of a National Institute on Alcohol Abuse and Alcoholism (NIAAA) P50 Center and a strong Brain Stimulation Research program, this multidisciplinary group of clinicians and neuroscientists has demonstrated) it is possible to differentially activate these circuits through TMS/Blood-oxygen-level-dependent (BOLD) imaging LTD-like TMS (cTBS) to the VMPFC decreases orbitofrontal cortex and ventral striatal/accumbens BOLD signal in heavy alcohol users cTBS also decreases alcohol cue reactivity in this population and in AUD patients currently enrolled in intensive outpatient treatment, 10 days of cTBS to the VMPFC is feasible, well-tolerated, increases 1 and 2 month retention rates, and attenuates limbic brain reactivity to alcohol cues after 1 month. While these studies provide a strong foundation for pursuing a larger multisite trial of cTBS, the CNDS theory and other alcohol TMS studies suggests that the DLPLC may also be a fruitful treatment target. In a sham-controlled pilot study the study team recently compared the efficacy of VMPFC cTBS to DLPFC iTBS, and, to the study team's surprise demonstrated that a single session of DLPFC iTBS had a greater effect on the brain response to alcohol cues than VMPFC cTBS. To resolve this gap in understanding, the investigator proposes a randomized, double-blind, sham-controlled clinical trial to evaluate the relative efficacy of these 2 strategies as novel tools to improve AUD treatment outcomes (e.g. percent days abstinent up to 4 months after TMS treatment initiation). These outcomes will be measured with urine ethyl glucuronide (ETG) and blood carbohydrate deficient transferrin (CDT) measurements. The study team will also evaluate the effect of these TBS treatments brain reactivity to alcohol cues. The investigator's long-term vision is that TBS would be used as an adjuvant to behavioral treatment, enabling individuals to maximize the likelihood of behavioral change.

180 treatment-seeking men and women recruited from the community at large, will be randomized to receive 15 visits of TMS (2x/day; 3x/week, 20-30 min intersession interval) of either real or sham TBS to the VMPFC or left DLPFC while they are enrolled in the proposed study. Randomization will occur after the participant has been consented and screened for eligibility and prior to the first treatment visit. Real/Sham TBS will be delivered three times per week for a total of 15 TMS visits. Quantitative ETG will be collected daily. Quantitative CDT will be collected monthly throughout the course of the study. Additional assessments and/or brain reactivity to alcohol cues will be measured at the following timepoints: baseline screening visit, MRI visit #1 (before TMS treatment visit 1), TMS treatment visits 1, 6, 11, and 15, MRI visit #2, and at the 3 monthly Follow Up visits. A saliva sample taken for genetic analysis of a specific Brain-derived neurotrophic factor (BDNF) variant will be obtained on enrollment and used to also analyze across these measures and individual outcomes in response to TMS. Building on recent pilot data, the study team will test the hypotheses that for both Strategy 1 & 2, real TBS will improve AUD treatment outcomes significantly more than sham. Analysis will be performed using repeated measures analysis of variance (ANOVA) on change scores from baseline for each visit. The main independent variable in the ANOVA will be time (TMS visits 1, 6, 11, and 15), group (VMPFC vs. DLPFC TBS vs. sham) and their interaction.

Aim 1 (Strategy 1): Modulating the limbic system: VMPFC cTBS. The study team will evaluate the effect of VMPFC cTBS, relative to sham, on number of days abstinent (primary outcome) and heavy drinking days in 30 day intervals for 4 months. Participants will receive stimulation over the left frontal pole electroencephalogram (EEG)10-20 system: Frontal Pole 1 (FP1). This location has been used in previous studies in alcohol users which demonstrate VMPFC target engagement.

Aim 2 (Strategy 2): Modulating the executive system: DLPFC iTBS. The study team will evaluate the effect of DLPFC iTBS, relative to sham, on the parameters listed. iTBS will be delivered over the left DLPFC EEG 10-20 system: Frontal 3 (F3) as this location has also been validated to reliable result in target engagement by this group.

Exploratory Aim- Baseline alcohol cue reactivity as a mediator of TBS clinical response. The study team will test the hypotheses that individuals with a higher ratio of (DLPFC-striatal)/(VMPFC-striatal) response to alcohol cues will be more likely to have a change in drinking after Strategy 2.

Details
Condition Alcohol abuse, Alcohol Use Disorder, Alcohol Use Disorders, Craving, Alcohol Dependence, alcoholism, alcohol dependence syndrome, chronic alcoholism
Treatment Real cTBS to the vmPFC, Sham cTBS to the vmPFC, Real iTBS to the dlPFC, Sham iTBS to the dlPFC
Clinical Study IdentifierNCT04154111
SponsorWake Forest University Health Sciences
Last Modified on12 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 21- 75
Meets the DSM V criteria for having a current AUD, determined by DSM-V criteria, using the Structured Clinical Interview for DSM-V
Has an AUDIT score above 8 (such that they are at least Medium Risk drinkers according to criteria)

Exclusion Criteria

Any psychoactive substance use (except marijuana and nicotine) within the last 30 days by self-report
Meets DSM V criteria for schizoaffective disorder. [Note: The inclusion of subjects with affective and anxiety disorders is essential because of the marked frequency of the co-existence of mood and other anxiety disorders among patients with AUD at large
Is currently taking or initiates a medication known to affect alcohol intake and/or craving (e.g., disulfiram. naltrexone, acamprosate, topiramate). [Note: This exclusionary criterion is for scientific rather than safety or patient comfort reasons]
Expects a change in their medical history in the next 6 months that would impair their participation in this study [e.g. expected medical procedure, planned pregnancy, initiation of new medication]
Suffers from chronic migraines (more than 50% of the days in a month)
Does not meet safety criteria for MRI and TMS
Is at elevated risk of seizure (i.e., has a history of seizures, is currently prescribed medications known to lower seizure threshold and has had a change in their medication)
Is currently enrolled in another form of treatment for alcohol use disorder (This is for scientific reasons to clarify the role of TMS as a treatment agent)
History of traumatic brain injury resulting in hospitalization, loss of consciousness for more than 10 minutes, and/or having ever been informed he/she has an epidural, subdural, or subarachnoid hemorrhage
Has current suicidal ideation or homicidal ideation
Not able to read and understand questionnaires, assessments, and the informed consent
Clinical Intake Withdrawal Assessment (CIWA) >5 (to prevent delivering TMS to individuals in withdrawal
Females of childbearing potential who are pregnant (by urine HCG), planning to become pregnant, nursing, or who are not using a reliable form of birth control
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note